Last Updated: 09 Nov 2024
Executive Summary
Bolt Biotherapeutics (BOLT) is a clinical-stage immuno-oncology company with a market capitalization of $249.2 million. The company is focused on the discovery, development, and commercialization of pharmaceutical products. Despite strong revenue growth, BOLT continues to operate at a loss, with an EBITDA of -$72.2 million and an EPS of -$1.74. The company's financial performance has led to a negative return on assets and equity. However, analysts remain cautiously optimistic, with five analysts rating the stock as a "Hold" and an analyst target price of $1.75.
Company Overview
Bolt Biotherapeutics is headquartered in Redwood City, California, and was founded in 2012. The company's mission is to develop innovative immunotherapies to treat cancer. BOLT's lead product candidate, BDC-1001, is a monoclonal antibody that targets the CD166 antigen. CD166 is expressed on the surface of tumor cells and plays a role in tumor growth and metastasis. BDC-1001 is currently in Phase 2 clinical trials for the treatment of advanced solid tumors.
Fundamental Analysis
BOLT's financial performance has been mixed. Revenue has grown significantly in recent quarters, with revenue TTM reaching $11.2 million. However, the company continues to operate at a loss, with an EBITDA of -$72.2 million and an EPS of -$1.74. The company's gross profit margin is 14.5%, and its operating margin TTM is -14.93%. BOLT's financial performance has led to a negative return on assets and equity of -0.294% and -0.58%, respectively.
Technical Analysis
BOLT's stock price has been volatile in recent months, trading between a 52-week high of $1.56 and a 52-week low of $0.545. The stock is currently trading at $0.65, below its 50-day and 200-day moving averages. The relative strength index (RSI) is 35.4, indicating that the stock is oversold.
Short Term Outlook
In the short term, BOLT's stock price is likely to remain volatile. The company's financial performance has been mixed, and the stock is trading below its moving averages. However, the company's lead product candidate, BDC-1001, is in Phase 2 clinical trials, and positive results from these trials could lead to a significant increase in the stock price.
Long Term Outlook
In the long term, BOLT's stock price is likely to be driven by the success of its clinical trials. If BDC-1001 is successful in clinical trials and approved by the FDA, BOLT could become a major player in the immuno-oncology market. However, if the clinical trials are unsuccessful, the stock price could decline significantly.
Analyst Recommendations
Five analysts currently cover BOLT, with five rating the stock as a "Hold." The analyst target price for BOLT is $1.75.
